{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:21Z","timestamp":1794047421627,"version":"4.8.0"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The somatic hypermutation (SHM) status of the clonotypic, rearranged immunoglobulin heavy variable (IGHV) gene is an established prognostic and predictive marker in chronic lymphocytic leukemia (CLL). Analysis of SHM is generally performed by polymerase chain reaction (PCR)-amplification of clonal IGHV-IGHD-IGHJ gene rearrangements followed by sequencing to identify IGHV gene sequences and germline identity. Targeted-hybridization next-generation sequencing (NGS) can simultaneously assess clonality and other genetic aberrations. However, it has limitations for SHM analysis due to sequence similarity between different IGHV genes and mutations introduced by SHM, which can affect alignment efficiency and accuracy. We developed a novel SHM assessment strategy using a targeted-hybridization NGS approach (EuroClonality- NDC assay) and applied it to 331 samples of lymphoproliferative disorder (LPD). Our strategy focuses on analyzing the sequence downstream to the clonotypic, rearranged IGHJ gene up to the IGHM enhancer (IGHJ-E) which provides more accurate alignment. Overall, 84\/95 (88.4%) CLL cases with conventional SHM data showed concordant SHM status, increasing to 91.6% when excluding borderline cases. Additionally, IGHJ-E mutation analysis in a wide range of pre- and post-germinal center LPD showed significant correlation with differentiation and lineage status, suggesting that IGHJ-E analysis is a promising surrogate marker enabling SHM to be reported using NGS-capture strategies and whole genome sequencing.<\/jats:p>","DOI":"10.3324\/haematol.2022.281928","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T05:31:18Z","timestamp":1672291878000},"page":"1313-1321","source":"Crossref","is-referenced-by-count":6,"title":["A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements"],"prefix":"10.3324","volume":"108","author":[{"given":"Neil","family":"McCafferty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Peter","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Darzentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Gazdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Catherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"47377","doi-asserted-by":"crossref","unstructured":"Goossens T, Klein U, Kuppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci U S A. 1998; 95(5):2463-2468.","DOI":"10.1073\/pnas.95.5.2463"},{"key":"47378","doi-asserted-by":"crossref","unstructured":"Liu M, Duke JL, Richter DJ. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008; 451(7180):841-845.","DOI":"10.1038\/nature06547"},{"key":"47379","doi-asserted-by":"crossref","unstructured":"Liu M, Schatz DG. Balancing AID and DNA repair during somatic hypermutation. Trends Immunol. 2009; 30(4):173-181.","DOI":"10.1016\/j.it.2009.01.007"},{"key":"47380","doi-asserted-by":"crossref","unstructured":"Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007; 76(1):1-22.","DOI":"10.1146\/annurev.biochem.76.061705.090740"},{"key":"47381","doi-asserted-by":"crossref","unstructured":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6):779-790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"47382","doi-asserted-by":"crossref","unstructured":"Fischer K, Hallek M. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):338-345.","DOI":"10.1182\/asheducation-2017.1.338"},{"key":"47383","doi-asserted-by":"crossref","unstructured":"Thompson PA, Tam CS, O'Brien SM. Fludarabine, cyclophosphamide, and rituximab treatment achieves longterm disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016; 127(3):303-309.","DOI":"10.1182\/blood-2015-09-667675"},{"key":"47384","doi-asserted-by":"crossref","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011; 118(16):4313-4320.","DOI":"10.1182\/blood-2011-06-338855"},{"key":"47385","doi-asserted-by":"crossref","unstructured":"Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012(1):88-96.","DOI":"10.1182\/asheducation.V2012.1.88.3801172"},{"key":"47386","doi-asserted-by":"crossref","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017; 92(9):946-965.","DOI":"10.1002\/ajh.24826"},{"key":"47387","doi-asserted-by":"crossref","unstructured":"Hallek M, Cheson BD, Catovsky D. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25):2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"47388","doi-asserted-by":"crossref","unstructured":"Rosenquist R, Ghia P, Hadzidimitriou A. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017; 31(7):1477-1481.","DOI":"10.1038\/leu.2017.125"},{"key":"47389","doi-asserted-by":"crossref","unstructured":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. 2022; 36(1):1961-1968.","DOI":"10.1038\/s41375-022-01604-2"},{"key":"47390","doi-asserted-by":"crossref","unstructured":"Gupta SK, Viswanatha DS, Patel KP. Evaluation of somatic hypermutation status in chronic lymphocytic leukemia (CLL) in the era of next generation sequencing. Front Cell Dev Biol. 2020; 8(1):357.","DOI":"10.3389\/fcell.2020.00357"},{"key":"47391","doi-asserted-by":"crossref","unstructured":"Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017; 92(12):1393-1397.","DOI":"10.1002\/ajh.24808"},{"key":"47392","doi-asserted-by":"crossref","unstructured":"Lefranc MP. Immunoglobulins: 25 years of immunoinformatics and IMGT-ONTOLOGY. Biomolecules. 2014; 4(4):1102-1139.","DOI":"10.3390\/biom4041102"},{"key":"47393","doi-asserted-by":"crossref","unstructured":"Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997; 89(11):4153-4160.","DOI":"10.1182\/blood.V89.11.4153"},{"key":"47394","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-1847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"47395","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6):1848-1854.","DOI":"10.1182\/blood.V94.6.1848"},{"key":"47396","doi-asserted-by":"crossref","unstructured":"Langerak AW, Davi F, Stamatopoulos K. Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. Br J Haematol. 2020; 189(5):809-810.","DOI":"10.1111\/bjh.16480"},{"key":"47397","doi-asserted-by":"crossref","unstructured":"Raponi S, Ilari C, Della Starza I. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. Br J Haematol. 2020; 189(5):853-859.","DOI":"10.1111\/bjh.16434"},{"key":"47398","doi-asserted-by":"crossref","unstructured":"Davis Z, Forconi F, Parker A. The outcome of chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with &lt;97% identity and similar to those with 98% identity. Br J Haematol. 2016; 173(1):127-136.","DOI":"10.1111\/bjh.13940"},{"key":"47399","doi-asserted-by":"crossref","unstructured":"Davi F, Langerak AW, de Septenville AL. Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia. 2020; 34(10):2545-2551.","DOI":"10.1038\/s41375-020-0923-9"},{"key":"47400","doi-asserted-by":"crossref","unstructured":"McClure R, Mai M, McClure S. High-throughput sequencing using the Ion Torrent personal genome machine for clinical evaluation of somatic hypermutation status in chronic lymphocytic leukemia. J Mol Diagn. 2015; 17(2):145-154.","DOI":"10.1016\/j.jmoldx.2014.11.006"},{"key":"47401","doi-asserted-by":"crossref","unstructured":"Stamatopoulos B, Timbs A, Bruce D. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. Leukemia. 2017; 31(4):837-845.","DOI":"10.1038\/leu.2016.307"},{"key":"47402","doi-asserted-by":"crossref","unstructured":"Rodriguez-Vicente AE, Bikos V, Hernandez-Sanchez M, Malcikova J, Hernandez-Rivas JM, Pospisilova S. Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. Oncotarget. 2017; 8(41):71234-71248.","DOI":"10.18632\/oncotarget.19525"},{"key":"47403","doi-asserted-by":"crossref","unstructured":"Wren D, Walker BA, Br\u00fcggemann M. Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica. 2017; 102(2):e57-e60.","DOI":"10.3324\/haematol.2016.155424"},{"key":"47404","unstructured":"Stewart JP, Gazdova J, Darzentas N. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Adv. 2021; 5(16):3188-3198."},{"key":"47405","doi-asserted-by":"crossref","unstructured":"Chandra V, Bortnick A, Murre C. AID targeting: old mysteries and new challenges. Trends Immunol. 2015; 36(9):527-535.","DOI":"10.1016\/j.it.2015.07.003"},{"key":"47406","doi-asserted-by":"crossref","unstructured":"Lebecque SG, Gearhart PJ. Boundaries of somatic mutation in rearranged immunoglobulin genes: 5' boundary is near the promoter, and 3' boundary is approximately 1 kb from V(D)J gene. J Exp Med. 1990; 172(6):1717-1727.","DOI":"10.1084\/jem.172.6.1717"},{"key":"47407","doi-asserted-by":"crossref","unstructured":"Bystry V, Reigl T, Krejci A. ARResT\/Interrogate: an interactive immunoprofiler for IG\/TR NGS data. Bioinformatics. 2017; 33(3):435-437.","DOI":"10.1093\/bioinformatics\/btw634"},{"key":"47408","doi-asserted-by":"crossref","unstructured":"Knecht H, Reigl T, Kotrova M. Quality control and quantification in IG\/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia. 2019; 33(9):2254-2265.","DOI":"10.1038\/s41375-019-0499-4"},{"key":"47409","doi-asserted-by":"crossref","unstructured":"Dunn T, Berry G, Emig-Agius D. Pisces: an accurate and versatile variant caller for somatic and germline next-generation sequencing data. Bioinformatics. 2019; 35(9):1579-1581.","DOI":"10.1093\/bioinformatics\/bty849"},{"key":"47410","doi-asserted-by":"crossref","unstructured":"Chen X, Schulz-Trieglaff O, Shaw R. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016; 32(8):1220-1222.","DOI":"10.1093\/bioinformatics\/btv710"},{"key":"47411","doi-asserted-by":"crossref","unstructured":"Robinson JT, Thorvaldsdottir H, Winckler W. Integrative genomics viewer. Nat Biotechnol. 2011; 29(1):24-26.","DOI":"10.1038\/nbt.1754"},{"key":"47412","doi-asserted-by":"crossref","unstructured":"Lefranc MP, Giudicelli V, Duroux P. IMGT(R), the international ImMunoGeneTics information system(R) 25 years on. Nucleic Acids Res. 2015; 43(1):D413-422.","DOI":"10.1093\/nar\/gku1056"},{"key":"47413","doi-asserted-by":"crossref","unstructured":"Jain P, Nogueras Gonz\u00e1lez GM, Kanagal-Shamanna R. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018; 180(1):33-40.","DOI":"10.1111\/bjh.15018"},{"key":"47414","doi-asserted-by":"crossref","unstructured":"Baliakas P, Moysiadis T, Hadzidimitriou A. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019; 104(2):360-369.","DOI":"10.3324\/haematol.2018.195032"},{"key":"47415","doi-asserted-by":"crossref","unstructured":"Morabito F, Shanafelt TD, Gentile M. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: mutational load or mutational status? Analysis of 1003 cases. Am J Hematol. 2018; 93(9):E216-E219.","DOI":"10.1002\/ajh.25206"},{"key":"47416","doi-asserted-by":"crossref","unstructured":"Maul RW, Gearhart PJ. Controlling somatic hypermutation in immunoglobulin variable and switch regions. Immunol Res. 2010; 47(1-3):113-122.","DOI":"10.1007\/s12026-009-8142-5"},{"key":"47417","doi-asserted-by":"crossref","unstructured":"Seifert M, Scholtysik R, K\u00fcppers R. Origin and pathogenesis of B cell lymphomas. Methods Mol Biol. 2013; 971(1):1-25.","DOI":"10.1007\/978-1-62703-269-8_1"},{"key":"47418","doi-asserted-by":"crossref","unstructured":"Seifert M, Sellmann L, Bloehdorn J. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012; 209(12):2183-2198.","DOI":"10.1084\/jem.20120833"},{"key":"47419","doi-asserted-by":"crossref","unstructured":"Carbone A, Gloghini A, Cabras A, Elia G. The germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol. 2009; 145(4):468-480.","DOI":"10.1111\/j.1365-2141.2009.07651.x"},{"key":"47420","doi-asserted-by":"crossref","unstructured":"de Leval L. Approach to nodal-based T-cell lymphomas. Pathology. 2020; 52(1):78-99.","DOI":"10.1016\/j.pathol.2019.09.012"},{"key":"47421","doi-asserted-by":"crossref","unstructured":"Bruggemann M, White H, Gaulard P. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies: report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia. 2007; 21(2):215-221.","DOI":"10.1038\/sj.leu.2404481"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281928\/75198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281928\/75566","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10927\/75198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:07Z","timestamp":1794045787000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281928","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}